Newsfiscal.ai
Eloxx Pharmaceuticals Finalizes Phase 2 ADPKD Trial Design and Appoints New CMO
· Published
Article summary
Eloxx Pharmaceuticals has finalized the design for its Phase 2 EXPRESS trial of exaluren in ADPKD and appointed T.R. Srinivas, M.D., as Chief Medical Officer.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…